Mankind Pharma Ltd. News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Mankind Pharma Ltd. from all sources in a single place.

Load latest

Mankind Pharma Ltd.

04 Aug 2024

2256.70

0.66%

Acquisition of BSV to aid future growth of Mankind Pharma: V-C Juneja

Business Standard

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja. On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore. "One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call. Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said. The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated. The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,

Mankind Pharma Ltd. has an average target of 2745.50 from 2 brokers.

Mankind Pharma Ltd.

31 Jul 2024

2256.70

0.66%

Mankind Pharma Q1 results: Profit up 9.9% at Rs 543 cr; revenue rises 12%

Business Standard

Mankind also announced a rise in its prescriber penetration to 83.2 per cent in Q1 FY25, from 82.7 per cent in the same quarter last financial year

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Q1 Results: Rising Exports Boost Revenue, But Margin Contracts

NDTV Profit | 31 Jul 2024 1 more

Mankind Pharma Ltd.

31 Jul 2024

2256.70

0.66%

to see Rapid results content

Mankind Pharma Ltd.

30 Jul 2024

2256.70

0.66%

Mankind Pharma targets women's health, fertility market

Business Today

Analysts indicate Mankind Pharma's capabilities in manufacturing complex molecules like Dydrogesterone would further strengthen its position in the women's health segment